228 related articles for article (PubMed ID: 16511899)
1. A decision aid to assist in adjuvant therapy choices for breast cancer.
Siminoff LA; Gordon NH; Silverman P; Budd T; Ravdin PM
Psychooncology; 2006 Nov; 15(11):1001-13. PubMed ID: 16511899
[TBL] [Abstract][Full Text] [Related]
2. Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information.
Peele PB; Siminoff LA; Xu Y; Ravdin PM
Med Decis Making; 2005; 25(3):301-7. PubMed ID: 15951457
[TBL] [Abstract][Full Text] [Related]
3. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
5. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
[TBL] [Abstract][Full Text] [Related]
7. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
8. A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients.
Ravdin PM
Bull Cancer; 1995 Dec; 82 Suppl 5():561s-564s. PubMed ID: 8680066
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making.
Chao C; Studts JL; Abell T; Hadley T; Roetzer L; Dineen S; Lorenz D; YoussefAgha A; McMasters KM
J Clin Oncol; 2003 Dec; 21(23):4299-305. PubMed ID: 14581440
[TBL] [Abstract][Full Text] [Related]
10. Utility of a web-based breast cancer predictive algorithm for adjuvant chemotherapeutic decision making in a multidisciplinary oncology center.
Epstein RJ; Leung TW; Mak J; Cheung PS
Cancer Invest; 2006; 24(4):367-73. PubMed ID: 16777688
[TBL] [Abstract][Full Text] [Related]
11. A computer program to assist in making breast cancer adjuvant therapy decisions.
Ravdin PM
Semin Oncol; 1996 Feb; 23(1 Suppl 2):43-50. PubMed ID: 8614844
[TBL] [Abstract][Full Text] [Related]
12. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
13. Pilot trial of a computerized decision aid for breast cancer prevention.
Ozanne EM; Annis C; Adduci K; Showstack J; Esserman L
Breast J; 2007; 13(2):147-54. PubMed ID: 17319855
[TBL] [Abstract][Full Text] [Related]
14. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
15. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Goss PE; Ingle JN; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Tu D
J Clin Oncol; 2008 Apr; 26(12):1948-55. PubMed ID: 18332475
[TBL] [Abstract][Full Text] [Related]
16. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients.
Kennedy T; Stewart AK; Bilimoria KY; Patel-Parekh L; Sener SF; Winchester DP
Ann Surg Oncol; 2007 Oct; 14(10):2918-27. PubMed ID: 17638060
[TBL] [Abstract][Full Text] [Related]
17. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
18. Exploring the black box of a decision aid: what information do patients select from an interactive Cd-Rom on treatment options in breast cancer?
Molenaar S; Sprangers M; Oort F; Rutgers E; Luiten E; Mulder J; van Meeteren M; de Haes H
Patient Educ Couns; 2007 Jan; 65(1):122-30. PubMed ID: 16945498
[TBL] [Abstract][Full Text] [Related]
19. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
